US4166105A
(en)
|
1973-07-30 |
1979-08-28 |
Block Engineering, Inc. |
Dye tagged reagent
|
SE430062B
(sv)
|
1977-03-04 |
1983-10-17 |
Pharmacia Fine Chemicals Ab |
Kopplings- eller tioleringsreagens
|
US4152411A
(en)
|
1977-07-27 |
1979-05-01 |
Akzona Incorporated |
High specific activity labeled substances
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
US4563304A
(en)
|
1981-02-27 |
1986-01-07 |
Pharmacia Fine Chemicals Ab |
Pyridine compounds modifying proteins, polypeptides or polysaccharides
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
US4664911A
(en)
|
1983-06-21 |
1987-05-12 |
Board Of Regents, University Of Texas System |
Immunotoxin conjugates employing toxin B chain moieties
|
DE3584012D1
(de)
|
1985-01-22 |
1991-10-10 |
Saint Gobain Vitrage |
Verfahren zur herstellung eines pulvers auf basis von indium-formiat zur herstellung einer duennen beschichtung auf einem substrat, insbesondere auf glas.
|
US5223242A
(en)
|
1985-11-05 |
1993-06-29 |
The General Hospital Corporation |
Negatively charged specific affinity reagents
|
GB8600582D0
(en)
|
1986-01-10 |
1986-02-19 |
Ca Minister Nat Defence |
Purifying biological materials
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
EP0247730A3
(en)
|
1986-04-28 |
1989-04-12 |
Antibody Technology Limited |
Antibodies, their preparation and use and products containing them
|
US4859449A
(en)
*
|
1987-09-14 |
1989-08-22 |
Center For Molecular Medicine And Immunology |
Modified antibodies for enhanced hepatocyte clearance
|
US5241078A
(en)
|
1988-06-14 |
1993-08-31 |
Cetus Oncology |
Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
|
JP2818827B2
(ja)
|
1988-06-24 |
1998-10-30 |
サンヨーファイン株式会社 |
鉄補給飲料
|
US5024834A
(en)
|
1988-07-12 |
1991-06-18 |
Cetus Corporation |
Thioether linked immunotoxin conjugates
|
CA2006408A1
(en)
|
1988-12-27 |
1990-06-27 |
Susumu Iwasa |
Bispecific monoclonal antibody, its production and use
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5714149A
(en)
*
|
1989-02-10 |
1998-02-03 |
Celltech Therapeutics Limited |
Crosslinked antibodies and processes for their preparation
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6316003B1
(en)
|
1989-12-21 |
2001-11-13 |
Whitehead Institute For Biomedical Research |
Tat-derived transport polypeptides
|
FR2656555B1
(fr)
|
1989-12-29 |
1994-10-28 |
Serimer |
Systeme mecanique de guidage automatique d'une ou plusieurs torches d'une unite de soudage a l'arc.
|
US5137877B1
(en)
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
DE69127627T2
(de)
|
1990-08-29 |
1998-02-19 |
Genpharm Int |
Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
CA2048078A1
(en)
|
1990-11-15 |
1992-05-16 |
Wolfgang A. Wrasidlo |
Chemical modification of antibodies for creation of immunoconjugates
|
US5252714A
(en)
|
1990-11-28 |
1993-10-12 |
The University Of Alabama In Huntsville |
Preparation and use of polyethylene glycol propionaldehyde
|
SE9102074D0
(sv)
|
1991-07-03 |
1991-07-03 |
Kabi Pharmacia Ab |
Tomour antigen specific antibody
|
SE470006B
(sv)
|
1991-09-26 |
1993-10-25 |
Corline Systems Ab |
Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
|
ATE463573T1
(de)
|
1991-12-02 |
2010-04-15 |
Medimmune Ltd |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
CA2076465C
(en)
|
1992-03-25 |
2002-11-26 |
Ravi V. J. Chari |
Cell binding agent conjugates of analogues and derivatives of cc-1065
|
US5501952A
(en)
|
1992-07-17 |
1996-03-26 |
Aprogenex, Inc. |
Analogues of reporter groups as background reducers in hybridization assays
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5556623A
(en)
|
1993-03-30 |
1996-09-17 |
Eli Lilly And Company |
Antibody-drug conjugates
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
GB9320575D0
(en)
|
1993-10-06 |
1993-11-24 |
Amp Gmbh |
Coaxial connector having improved locking mechanism
|
IL111748A0
(en)
|
1993-12-03 |
1995-01-24 |
Zeneca Ltd |
Proteins
|
US5919758A
(en)
|
1994-03-22 |
1999-07-06 |
Beth Israel Deaconess Medical Center |
Modified polypeptides with altered biological activity
|
US5580853A
(en)
|
1994-03-22 |
1996-12-03 |
New England Deaconess Hospital |
Modified polypeptides with increased biological activity
|
US5747446A
(en)
|
1994-03-22 |
1998-05-05 |
Beth Israel Deaconess Medical Center |
Modified polypeptides with increased biological activity
|
US5612474A
(en)
|
1994-06-30 |
1997-03-18 |
Eli Lilly And Company |
Acid labile immunoconjugate intermediates
|
US6355780B1
(en)
|
1995-02-22 |
2002-03-12 |
Yeda Research And Development Co. Ltd. |
Antibodies to the death domain motifs of regulatory proteins
|
WO1996039183A1
(en)
|
1995-05-31 |
1996-12-12 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for targeted delivery of effector molecules
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
WO1998026747A2
(en)
*
|
1996-12-17 |
1998-06-25 |
Terman David S |
Superantigen based methods and compositions for treatment of diseases
|
US6462070B1
(en)
|
1997-03-06 |
2002-10-08 |
The General Hospital Corporation |
Photosensitizer conjugates for pathogen targeting
|
US6371975B2
(en)
|
1998-11-06 |
2002-04-16 |
Neomend, Inc. |
Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
|
DE69827507T2
(de)
|
1997-06-11 |
2006-03-09 |
Borean Pharma A/S |
Trimerisierendes modul
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US5958677A
(en)
|
1997-07-28 |
1999-09-28 |
The New York Blood Center, Inc. |
Method for purifying viral nucleic acids
|
CA2297070A1
(en)
|
1997-08-01 |
1999-02-11 |
Morphosys Ag |
Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
|
US5965714A
(en)
|
1997-10-02 |
1999-10-12 |
Connaught Laboratories, Inc. |
Method for the covalent attachment of polysaccharides to protein molecules
|
KR100680014B1
(ko)
|
1997-10-03 |
2007-02-09 |
갈레니카 파마슈티칼스 인크. |
이민 형성 폴리사카라이드, 이의 제조 방법 및 이것의 아쥬반트 및 면역자극제로서의 용도
|
US6121236A
(en)
|
1998-03-24 |
2000-09-19 |
The Children's Medical Center Corporation |
Multivalent ligands which modulate angiogenesis
|
AU760669B2
(en)
|
1998-04-28 |
2003-05-22 |
Galenica Pharmaceuticals, Inc. |
Polysaccharide-antigen conjugates
|
US5981564A
(en)
|
1998-07-01 |
1999-11-09 |
Universite Laval |
Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
|
WO2000002587A1
(en)
|
1998-07-13 |
2000-01-20 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
|
ATE294803T1
(de)
|
1998-08-27 |
2005-05-15 |
Spirogen Ltd |
Pyrrolobenzodiazepine
|
AUPQ014799A0
(en)
|
1999-05-04 |
1999-05-27 |
Access Pharmaceuticals Australia Pty Limited |
Amplification of folate-mediated targeting to tumor cells using polymers
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
JP2003514903A
(ja)
|
1999-11-24 |
2003-04-22 |
イムノージェン インコーポレーテッド |
タキサンを含有する細胞傷害薬とその治療への利用
|
DE60031793T2
(de)
|
1999-12-29 |
2007-08-23 |
Immunogen Inc., Cambridge |
Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
|
JP2004511425A
(ja)
|
2000-02-08 |
2004-04-15 |
ザ ペン ステート リサーチ ファウンデーション |
免疫療法に使用されるインターロイキン13受容体サブユニットアルファー2
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US6632979B2
(en)
*
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
US6596503B1
(en)
|
2000-08-18 |
2003-07-22 |
East Carolina University |
Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
|
US20060062786A1
(en)
*
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
IL157142A0
(en)
|
2001-01-29 |
2004-02-08 |
Idec Pharma Corp |
Modified antibodies and methods of use
|
DE60214134T2
(de)
|
2001-02-07 |
2007-07-19 |
Beth Israel Deaconess Medical Center, Boston |
Modifizierte psma-liganden und deren verwendung
|
EP1389090A2
(en)
*
|
2001-04-26 |
2004-02-18 |
Board of Regents, The University of Texas System |
Diagnostic imaging compositions, their methods of synthesis and use
|
JP2004533449A
(ja)
|
2001-05-11 |
2004-11-04 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
Cd26を発現している細胞に関連する疾患の治療としての抗cd26モノクローナル抗体
|
EP1258255A1
(en)
|
2001-05-18 |
2002-11-20 |
Boehringer Ingelheim International GmbH |
Conjugates of an antibody to CD44 and a maytansinoid
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
JP4619651B2
(ja)
|
2001-06-01 |
2011-01-26 |
コーネル・リサーチ・ファンデーション・インコーポレイテッド |
前立腺特異的膜抗原に対する修飾抗体およびその使用
|
US6576802B2
(en)
|
2001-06-04 |
2003-06-10 |
Shell Oil Company |
One-step production of 1, 3-propanediol from ethylene oxide and syngas with a catalyst with a phospholanoalkane ligand
|
JP2005532415A
(ja)
|
2001-12-11 |
2005-10-27 |
メルク エンド カムパニー インコーポレーテッド |
スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
EP1467758A4
(en)
|
2002-01-03 |
2007-11-14 |
Smithkline Beecham Corp |
PREPARATION OF IMMUNOCONJUGATES
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US6660856B2
(en)
|
2002-03-08 |
2003-12-09 |
Kaohsiung Medical University |
Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues
|
US6534660B1
(en)
|
2002-04-05 |
2003-03-18 |
Immunogen, Inc. |
CC-1065 analog synthesis
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
EP1501369B1
(en)
|
2002-04-26 |
2015-06-24 |
Genentech, Inc. |
Non-affinity purification of proteins
|
DK1507556T3
(en)
*
|
2002-05-02 |
2016-09-12 |
Wyeth Holdings Llc |
Calicheamicin derivative-carrier conjugates
|
US20090068178A1
(en)
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
US6596757B1
(en)
|
2002-05-14 |
2003-07-22 |
Immunogen Inc. |
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
|
EP1551875A4
(en)
|
2002-06-21 |
2006-06-28 |
Biogen Idec Inc |
TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
AU2003259163B2
(en)
|
2002-08-16 |
2008-07-03 |
Immunogen, Inc. |
Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
|
AU2003273413A1
(en)
|
2002-10-08 |
2004-05-04 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
CN106337046B
(zh)
|
2002-10-30 |
2021-03-23 |
纽韦卢森公司 |
合成双功能复合物的方法
|
JP5354835B2
(ja)
|
2002-11-07 |
2013-11-27 |
イミュノジェン・インコーポレーテッド |
抗cd33抗体、及びそれを用いた急性骨髄性白血病の治療方法
|
US6884799B2
(en)
|
2003-03-31 |
2005-04-26 |
Council Of Scientific And Industrial Research |
Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof
|
EP2666858A1
(en)
|
2003-04-17 |
2013-11-27 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
KR101441358B1
(ko)
|
2003-05-14 |
2014-09-24 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
US8088387B2
(en)
*
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
ES2559670T3
(es)
*
|
2003-05-20 |
2016-02-15 |
Immunogen, Inc. |
Agentes citotóxicos mejorados que comprenden nuevos maitansinoides
|
US7276497B2
(en)
*
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
US7595306B2
(en)
|
2003-06-09 |
2009-09-29 |
Alnylam Pharmaceuticals Inc |
Method of treating neurodegenerative disease
|
DK3604537T3
(da)
|
2003-06-13 |
2022-02-28 |
Alnylam Europe Ag |
Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
|
KR20140142311A
(ko)
|
2003-06-27 |
2014-12-11 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
US20050074425A1
(en)
|
2003-07-02 |
2005-04-07 |
Polycord, Inc. |
Method for delivering polymerized therapeutic agent compositions and compositions thereof
|
CA2542886A1
(en)
|
2003-11-05 |
2005-05-19 |
Neelima M. Bhat |
Enhanced b cell cytotoxicity of cdim binding antibody
|
CA2758460C
(en)
|
2003-12-16 |
2014-09-23 |
Nektar Therapeutics |
Methods of preparing monodisperse oligo (ethylene glycol) reagent compositions
|
US20050175619A1
(en)
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
US20110064754A1
(en)
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
WO2005094882A1
(en)
|
2004-03-03 |
2005-10-13 |
Millennium Pharmaceuticals, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
US6951853B1
(en)
|
2004-03-30 |
2005-10-04 |
Council Of Scientific And Industrial Research |
Process for preparing pyrrolo[2, 1-c] [1,4] benzodiazepine hybrids
|
US7189710B2
(en)
|
2004-03-30 |
2007-03-13 |
Council Of Scientific And Industrial Research |
C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
WO2006078278A2
(en)
|
2004-04-27 |
2006-07-27 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
|
EP1750776A2
(en)
|
2004-04-30 |
2007-02-14 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a c5-modified pyrimidine
|
US20060073528A1
(en)
|
2004-05-14 |
2006-04-06 |
Jean-Michel Lecerf |
Measurement methods
|
NZ550934A
(en)
|
2004-05-19 |
2010-05-28 |
Medarex Inc |
Chemical linkers and conjugates thereof
|
US7691962B2
(en)
*
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
CA2572151A1
(en)
|
2004-06-30 |
2006-08-24 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a non-phosphate backbone linkage
|
WO2006093526A2
(en)
|
2004-07-21 |
2006-09-08 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a modified or non-natural nucleobase
|
JP4193771B2
(ja)
|
2004-07-27 |
2008-12-10 |
セイコーエプソン株式会社 |
階調電圧発生回路及び駆動回路
|
EP1913011B1
(en)
|
2004-08-04 |
2016-11-02 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
|
CA2486285C
(en)
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
AR052774A1
(es)
*
|
2004-10-08 |
2007-04-04 |
Wyeth Corp |
Inmunoterapia para trastornos autoinmunes
|
EP1817341A2
(en)
|
2004-11-29 |
2007-08-15 |
Seattle Genetics, Inc. |
Engineered antibodies and immunoconjugates
|
PT1819359E
(pt)
|
2004-12-09 |
2015-05-28 |
Janssen Biotech Inc |
Imunoconjugados anti-integrina, métodos para a sua produção e sua utilização
|
US7408030B2
(en)
|
2005-01-13 |
2008-08-05 |
North Carolina State University |
Purification of immunoglobulins using affinity chromatography and peptide ligands
|
US7811572B2
(en)
*
|
2005-08-24 |
2010-10-12 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
CA2597407C
(en)
|
2005-02-11 |
2013-09-10 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
US20110166319A1
(en)
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
BRPI0608175A2
(pt)
|
2005-04-15 |
2009-11-10 |
Immunogen Inc |
método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
|
GB2427360A
(en)
|
2005-06-22 |
2006-12-27 |
Complex Biosystems Gmbh |
Aliphatic prodrug linker
|
BRPI0613005A8
(pt)
|
2005-07-15 |
2017-12-26 |
Angiochem Inc |
uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
|
CA2615122A1
(en)
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
US20070213292A1
(en)
|
2005-08-10 |
2007-09-13 |
The Rockefeller University |
Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
|
CN101443044A
(zh)
|
2005-09-22 |
2009-05-27 |
哈达斯特医学研究服务与开发有限公司 |
治疗活性化合物的葡聚糖和阿拉伯半乳聚糖结合物
|
CA2623652C
(en)
*
|
2005-09-26 |
2013-11-26 |
Medarex, Inc. |
Antibody-drug conjugates and methods of use
|
EP1959958A4
(en)
|
2005-11-14 |
2010-07-14 |
Univ Southern California |
INTEGRIN-BINDING SMALL MOLECULES
|
JP5102772B2
(ja)
|
2005-11-29 |
2012-12-19 |
ザ・ユニバーシティ・オブ・シドニー |
デミボディ:二量体化活性化治療剤
|
WO2007098611A1
(en)
|
2006-03-03 |
2007-09-07 |
Queen's University At Kingston |
Compositions for treatment of cancer
|
US7964415B2
(en)
|
2006-04-26 |
2011-06-21 |
Cardiogenics Inc. |
Stable water-soluble polyethylenimine conjugates and methods of use thereof
|
EP2446904B1
(en)
*
|
2006-05-30 |
2015-04-29 |
Genentech, Inc. |
Anti-CD22 antibodies, their immunoconjugates and uses thereof
|
WO2007147213A1
(en)
|
2006-06-22 |
2007-12-27 |
Walter And Eliza Hall Institute Of Medical Research |
Structure of the insulin receptor ectodomain
|
USRE47123E1
(en)
|
2006-07-18 |
2018-11-13 |
Sanofi |
EPHA2 receptor antagonist antibodies
|
US20080213349A1
(en)
|
2006-09-11 |
2008-09-04 |
Deepak Ramesh Thakker |
Liposome Complexes Containing Pharmaceutical Agents and Methods
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
PL2019104T3
(pl)
|
2007-07-19 |
2014-03-31 |
Sanofi Sa |
Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
|
US8084589B2
(en)
|
2007-08-31 |
2011-12-27 |
University Of Massachusetts |
Phosphoramidite nucleoside analogs
|
JP2011523628A
(ja)
*
|
2008-04-30 |
2011-08-18 |
イミュノジェン・インコーポレーテッド |
有効なコンジュゲートおよび親水性リンカー
|
CN104524590B
(zh)
|
2008-04-30 |
2019-06-21 |
伊缪诺金公司 |
交联剂和它们的用途
|
GB0811743D0
(en)
|
2008-06-26 |
2008-07-30 |
Hemosol Biopharma Inc |
Composition
|
CN102215820A
(zh)
|
2008-11-17 |
2011-10-12 |
安龙制药公司 |
用于核酸输送系统的可释放融合脂质
|
CN105175434A
(zh)
|
2009-02-05 |
2015-12-23 |
伊缪诺金公司 |
新型苯并二氮杂*衍生物
|
SI2437790T1
(sl)
|
2009-06-03 |
2019-07-31 |
Immunogen, Inc. |
Konjugacijske metode
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
KR102287474B1
(ko)
|
2010-02-24 |
2021-08-06 |
이뮤노젠 아이엔씨 |
엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
|
KR20110103182A
(ko)
|
2010-03-12 |
2011-09-20 |
삼성전자주식회사 |
입체 영상 표시 장치
|
US20120149732A1
(en)
|
2010-12-14 |
2012-06-14 |
Alexander Chucholowski |
Multifunctional linkers and methods for the use thereof
|
EP3498303A1
(en)
|
2011-02-15 |
2019-06-19 |
ImmunoGen, Inc. |
Methods of preparation of conjugates
|
EA201991268A3
(ru)
|
2011-03-29 |
2020-01-31 |
Иммуноджен, Инк. |
Получение конъюгатов "майтансиноид-антитело" одностадийным способом
|
EP2691117A2
(en)
|
2011-03-29 |
2014-02-05 |
Immunogen, Inc. |
Process for manufacturing conjugates of improved homogeneity
|
SG193996A1
(en)
|
2011-03-29 |
2013-11-29 |
Immunogen Inc |
Preparation of maytansinoid antibody conjugates by a one-step process
|
IL281714B2
(en)
|
2011-04-01 |
2023-11-01 |
Immunogen Inc |
Methods for increasing the effectiveness of FOLR1 cancer therapy
|
US20130071482A1
(en)
|
2011-09-20 |
2013-03-21 |
The University Of Kentucky Research Foundation |
Block copolymer cross-linked nanoassemblies as modular delivery vehicles
|
WO2013090590A1
(en)
|
2011-12-13 |
2013-06-20 |
Immunogen, Inc. |
Use of n-hydroxysuccinimide to improve conjugate stability
|
WO2014055893A1
(en)
|
2012-10-04 |
2014-04-10 |
Immunogen, Inc. |
Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates
|
US20150306242A1
(en)
|
2012-10-04 |
2015-10-29 |
Immunogen, Inc. |
Process for preparing stable antibody maytansinoid conjugates
|
RU2661083C2
(ru)
|
2012-10-04 |
2018-07-11 |
Иммуноджен, Инк. |
Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
|
US10253099B2
(en)
|
2012-12-05 |
2019-04-09 |
Ruprecht-Karls-Universität Heidelberg |
Conjugates of proteins and multivalent cell-penetrating peptides and their uses
|